Eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA] and other omega-3 fatty acids have been extensively studied for their cardiovascular importance. They have anti-inflammatory, antiarrhythmic, and lipid-modulating properties. Omega-3 supplementation has been intensely studied for its effect on cardiac health in relation to its efficacy and safety in preventing cardiac events. Insights into its benefits and associated risks, in particular, are based on randomized controlled trials and systematic reviews, especially when high-dose EPA formulations are recommended. Although there have been conflicting studies, there appears to be some evidence that high-dose EPA formulations may reduce cardiovascular events. Their application is further complicated by safety concerns [increased atrial fibrillation risk and bleeding tendencies]. Nevertheless, tailored omega-3 interventions are likely to be of significant benefit to certain subgroups, such as those with high triglycerides or a high cardiovascular risk. The data suggest that omega-3 supplementation should be taken carefully to avoid the risks of therapeutic benefit. A foundation for advancing personalized cardiovascular therapies and improving clinical outcomes is given by additional insights into dosage, formulation, and patient characteristics.
Cite this paper
Arabiyat, L. , AL-Zioud, L. , Arabiat, H. , Arabiyat, A. and AL-Zioud, M. (2025). Omega-3 Fish Oil Safety and Efficacy for Cardiac Patients. Open Access Library Journal, 12, e3160. doi: http://dx.doi.org/10.4236/oalib.1113160.
Kotwal, S., Jun, M., Sullivan, D., Perkovic, V. and Neal, B. (2012) Omega 3 Fatty Acids and Cardiovascular Outcomes. Circula-tion: Cardiovascular Quality and Outcomes, 5, 808-818. https://doi.org/10.1161/circoutcomes.112.966168
Yan, J., Liu, M., Yang, D., Zhang, Y. and An, F. (2022) Effi-cacy and Safety of Omega-3 Fatty Acids in the Prevention of Cardiovascular Disease: A Systematic Review and Me-ta-Analysis. Cardiovascular Drugs and Therapy, 38, 799-817. https://doi.org/10.1007/s10557-022-07379-z
Khan, S.U., Lone, A.N., Khan, M.S., Virani, S.S., Blumenthal, R.S., Nasir, K., et al. (2021) Effect of Omega-3 Fatty Acids on Cardio-vascular Outcomes: A Systematic Review and Meta-Analysis. eClinicalMedicine, 38, Article ID: 100997. https://doi.org/10.1016/j.eclinm.2021.100997
Jaca, A., Durão, S., Harbron, J., et al. (2020) Omega-3 Fatty Acids for the Primary and Secondary Prevention of Cardiovascular Disease. Cochrane Database of Systematic Reviews, 3, CD003177.
Abdelhamid, A.S., Brown, T.J., Brainard, J.S., et al. (2018) Omega-3 Fatty Acids for the Primary and Sec-ondary Prevention of Cardiovascular Disease. Cochrane Database of Systematic Reviews, 7, CD003177.
Rawat, A., Khare, A., Suradkar, N., et al. (2024) A Study on Omega-3 Fish Oil Safety and Efficacy for Cardiac Patients. Frontiers in Health Informatics, 13, 826-837.
Skulas-Ray, A.C., Wilson, P.W.F., Harris, W.S., Brinton, E.A., Kris-Etherton, P.M., Richter, C.K., et al. (2019) Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory from the American Heart Association. Circulation, 140, e673-e691. https://doi.org/10.1161/cir.0000000000000709
Bernasconi, A.A., Wiest, M.M., Lavie, C.J., Milani, R.V. and Lauk-kanen, J.A. (2021) Effect of Omega-3 Dosage on Cardiovascular Outcomes: An Updated Meta-Analysis. Mayo Clinic Pro-ceedings, 96, 304-313. https://doi.org/10.1016/j.mayocp.2020.08.034
Sherratt, S.C.R., Libby, P., Budoff, M.J., Bhatt, D.L. and Mason, R.P. (2022) Role of Omega-3 Fatty Acids in Cardiovascular Disease: The Debate Continues. Current Atherosclerosis Reports, 25, 1-17. https://doi.org/10.1007/s11883-022-01075-x
Abdelhamid, A., Brown, T., Brainard, J., et al. (2020) Omega-3 Fatty Acid Supplementation and Risk of Atrial Fibrillation. European Heart Jour-nal—Cardiovascular Pharmacotherapy, 7, 59-70.
Glück, T. and Alter, P. (2016) Marine Omega-3 Highly Unsaturated Fatty Acids: From Mechanisms to Clinical Implications in Heart Failure and Arrhythmias. Vascular Pharmacology, 82, 11-19. https://doi.org/10.1016/j.vph.2016.03.007